The maker of treatments and therapies for eye diseases raised $65 million after selling 5 million shares at $13 per share. The pricing is below its previously expected range of between $14 and $16 per share. Ocular plans to use the money it raised to complete clinical trials of its treatments, for marketing expenses and to buy manufacturing equipment. Its shares rose 15 cents to $13.15 on the Nasdaq exchange. The shares trade under the symbol "OCUL." The company is based in Bedford, Massachusetts.
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.
Address
Ste 101, 36 Crosby Drive
BEDFORD, MA 01730
United States
BEDFORD, MA 01730
United States
Website
http://www.ocutx.comKey stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | -25955.55% | - |
| Operating margin | -25277.78% | - |
| EBITD margin | - | - |
| Return on average assets | - | -59.94% |
| Return on average equity | - | - |
| Employees | 58 |
No comments:
Post a Comment